36,254 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 36,254 shares of the specialty pharmaceutical company's stock, valued at approximately $1,049,000. Assenagon Asset Management S.A. owned about 0.07% of Supernus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Natixis Advisors L.P. raised its position in shares of Supernus Pharmaceuticals by 15.3% during the 1st quarter. Natixis Advisors L.P. now owns 31,126 shares of the specialty pharmaceutical company's stock worth $1,006,000 after purchasing an additional 4,129 shares during the period. Bank of Montreal Can raised its position in shares of Supernus Pharmaceuticals by 10.3% during the 1st quarter. Bank of Montreal Can now owns 15,996 shares of the specialty pharmaceutical company's stock worth $519,000 after purchasing an additional 1,488 shares during the period. MetLife Investment Management LLC raised its position in shares of Supernus Pharmaceuticals by 54.9% during the 1st quarter. MetLife Investment Management LLC now owns 27,869 shares of the specialty pharmaceutical company's stock worth $901,000 after purchasing an additional 9,872 shares during the period. Rhumbline Advisers raised its position in shares of Supernus Pharmaceuticals by 2.4% during the 1st quarter. Rhumbline Advisers now owns 148,330 shares of the specialty pharmaceutical company's stock worth $4,794,000 after purchasing an additional 3,477 shares during the period. Finally, Sei Investments Co. raised its position in shares of Supernus Pharmaceuticals by 2.4% during the 1st quarter. Sei Investments Co. now owns 223,149 shares of the specialty pharmaceutical company's stock worth $7,217,000 after purchasing an additional 5,196 shares during the period.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 14,491 shares of the firm's stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total value of $511,677.21. Following the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, VP Padmanabh P. Bhatt sold 14,491 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total transaction of $511,677.21. Following the transaction, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Tami Tillotson Martin sold 8,000 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $27.91, for a total value of $223,280.00. Following the transaction, the vice president now owns 85,664 shares in the company, valued at $2,390,882.24. The disclosure for this sale can be found here. Insiders have sold a total of 43,739 shares of company stock worth $1,450,713 in the last three months. 8.76% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, Piper Sandler dropped their price target on Supernus Pharmaceuticals from $45.00 to $41.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 28th.

Supernus Pharmaceuticals Stock Up 0.9 %

SUPN traded up $0.31 during trading hours on Friday, hitting $33.55. The company's stock had a trading volume of 242,946 shares, compared to its average volume of 429,547. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $21.99 and a fifty-two week high of $39.09. The company has a 50-day simple moving average of $30.83 and a 200 day simple moving average of $28.36.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.39). Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The business had revenue of $164.30 million during the quarter, compared to analyst estimates of $155.03 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The firm's revenue was down 1.8% compared to the same quarter last year. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.